Results

Scientific results are shown on posters at congresses

Generally, RABBIT shows biologic DMARDs to be effective, safe and well tolerated in daily rheumatologic care. Used by experienced rheumatologists, they are a safe treatment option for patients with rheumatoid arthritis, who do not respond adequately to non-biologic DMARDs.

In practice, biologic DMARDs are not prescribed until non-biologic DMARDs fail or are not tolerated. That means that patients for whom biologic DMARDs are indicated differ systematically from patients who are treated with non-biologic DMARDs. Therefore, highly sophisticated statistical methods are required to compare patients on biologic and non-biologic DMARDs.

Here, we will give a short insight into our published results: Original publications

Eingeschlossene Patienten: 23.474 (Stand 07. April 2025)
Amgevita® (Adalimumab)249
Benepali® (Etanercept)1273
Cimzia® (Certolizumab)1049
Enbrel® (Etanercept)2878
Erelzi® (Etanercept)596
Flixabi® (Infliximab)10
Hukyndra® (Adalimumab)15
Hulio® (Adalimumab)290
Humira® (Adalimumab)2912
Hyrimoz® (Adalimumab)264
Idacio® (Adalimumab)69
Imraldi® (Adalimumab)245
Inflectra™ (Infliximab)16
Jyseleca® (Filgotinib)170
Kevzara® (Sarilumab)231
Kineret® (Anakinra)89
MabThera® (Rituximab)1459
Nepexto® (Etanercept)101
Olumiant® (Baricitinib)554
Orencia® (Abatacept)996
Remicade® (Infliximab)762
Remsima® (Infliximab)27
Rinvoq® (Upadacitinib)329
Rixathon® (Rituximab)20
RoActemra® (Tocilizumab)1379
Ruxience® (Rituximab)1
Simponi® (Golimumab)479
Truxima® (Rituximab)5
Tyenne® (Tocilizumab)57
Xeljanz® (Tofacitinib)403
Yuflyma® (Adalimumab)56
Zessly® (Infliximab)2
Kontrollen6488